| Name | Title | Contact Details |
|---|
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.
The Critical Path Institute is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Barnett and Ramel Optical is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PMI Labs is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nuvaira, Inc., is a privately held medical device company that develops minimally invasive products to make breathing easier for patients suffering from obstructive lung diseases.